Vivasc Therapeutics, founded to advance cardiac drug development, focuses on pioneering solutions for atrial fibrillation (AFiB) and other cardiology-related conditions. Utilizing their proprietary Cardiac Targeting Peptide (CTP) platform technology, they aim to deliver therapeutic cargo directly to cardiomyocytes non-invasively. Their services encompass drug development and innovative cardiology treatments, targeting a niche market in pre-clinical cardiac therapeutics.
Notable achievements include receiving multiple NIH Phase I STTR grants, underscoring their credibility and potential in the scientific community. Vivasc Therapeutics collaborates with various partners to expand the applications of their CTP platform. Their work has a significant impact on advancing non-invasive cardiac treatments, positioning them as a key player in the pre-clinical drug development sector.
